COMP <GO>
CTKB vs ABBV // 10Y YIELD & FRED MACRO BETA
Cytek Biosciences Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: CTKB 1
— ABBV 10
■ METRIC PARITY
LAST: $6.30 (+2.61%) • MKT CAP: $818.9M
macro-sensitivity
—
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
macro-sensitivity
1.15
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CTKB VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CTKB | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 51.80% | 70.20% | -18.40 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -12.70% | 29.00% | -41.70 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.07% | 3.47% | -4.54 | ABBV | /fcf-yield <GO> |
| Operating Margin | -20.00% | 24.60% | -44.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -33.00% | 6.90% | -39.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 0.50% | 8.60% | -8.10 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.76 | 5.33 | -0.57 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 7/9 | -4.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 65.6 | 65.1 | +0.53 | CTKB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $818.9M | $513.86B | -$513.04B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CTKB REV | ABBV REV | CTKB GROSS % | ABBV GROSS % | CTKB FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $201.5M | $61.16B | 51.8% | 70.2% | -$8.8M | $17.82B |
| FY 2024 | $200.5M | $56.33B | 55.4% | 70.0% | $21.9M | $17.83B |
| FY 2023 | $193.0M | $54.32B | — | — | $5.3M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CTKB // BETA —
ABBV // BETA 1.15